Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SEEMAL R DESAI

Allopathic & Osteopathic Physicians Dermatology

NPI
1669686804
CMS profile
348419
Location
PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$271,842.31

226 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SEEMAL R DESAI

NPI 1669686804 · CMS profile ID 348419

Allopathic & Osteopathic Physicians / Dermatology

PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669686804?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SEEMAL R DESAI, NPI 1669686804, CMS profile ID 348419. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669686804?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). SEEMAL R DESAI, NPI 1669686804, CMS profile ID 348419. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669686804?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
SEEMAL R DESAI, NPI 1669686804, CMS profile ID 348419, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1669686804?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

226 matching records · $271,842.31 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 226 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 226.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $189.1410/08/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1229493656 CMS
Arcutis Biotherapeutics, Inc. $7.4910/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252371495 CMS
PFIZER INC. $3,400.0010/06/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1229428810 CMS
Incyte Corporation $60.6610/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226016660 CMS
Incyte Corporation $234.4810/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226016656 CMS
Incyte Corporation $105.0910/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226016738 CMS
Incyte Corporation $150.1010/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226018705 CMS
Lilly USA, LLC $3,200.0010/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186874061 CMS
Lilly USA, LLC $1,200.0010/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186937458 CMS
Lilly USA, LLC $44.7110/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186937460 CMS
Incyte Corporation $17.3210/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226018407 CMS
Incyte Corporation $1,093.7510/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1226021849 CMS
LEO Pharma Inc. $1,200.0010/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1252001313 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $51.5710/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251057545 CMS
Lilly USA, LLC $24.4610/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186874063 CMS
SANOFI PASTEUR INC. $3,992.0009/30/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1227023646 CMS
Arcutis Biotherapeutics, Inc. $4,037.5009/26/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1252371501 CMS
Lilly USA, LLC $1,600.0009/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186937456 CMS
PFIZER INC. $2,125.0009/25/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1229084708 CMS
PFIZER INC. $850.0009/25/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1229281883 CMS
Incyte Corporation $5.0109/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226029821 CMS
PFIZER INC. $72.7009/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230156425 CMS
LNHC, Inc $1,500.0009/10/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1242601980 CMS
Janssen Scientific Affairs, LLC $1,062.5009/08/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1174205137 CMS
LEO Pharma Inc. $1,850.0009/08/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1252001309 CMS
LEO Pharma Inc. $17.6709/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252001311 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $8,100.0009/04/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1220087420 CMS
PFIZER INC. $2,550.0009/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1229123373 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $4.0508/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1220087408 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $250.7408/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1220087410 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $6.9208/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1220087412 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $582.9708/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1220087414 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $78.7108/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1220087416 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $6.7508/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1220087418 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $16.1208/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1220087422 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $27.7208/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1220087424 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $124.6708/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1220087426 CMS
Janssen Biotech, Inc. $2,125.0008/23/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1175113394 CMS
ABBVIE INC. $121.9108/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201754820 CMS
GENZYME CORPORATION $75.6108/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233644322 CMS
GENZYME CORPORATION $280.5608/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233644342 CMS
LEO Pharma Inc. $19.7408/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252001307 CMS
Lilly USA, LLC $1,600.0008/15/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186937454 CMS
Janssen Biotech, Inc. $139.2708/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175112194 CMS
PFIZER INC. $4,886.0008/11/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1229067828 CMS
Arcutis Biotherapeutics, Inc. $4,750.0008/09/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1252371493 CMS
Incyte Corporation $5,250.0008/08/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1226016324 CMS
Incyte Corporation $5,687.5008/08/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1226018055 CMS
UCB, Inc. $2,700.0008/05/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1224767472 CMS
LEO Pharma Inc. $2.6807/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252001303 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $75,356.55 69
PY2020 $101,994.10 41
PY2021 $125,495.54 71
PY2022 $165,158.87 118
PY2023 $35,058.06 54
PY2024 $2,477.30 24
PY2025 $271,842.31 226

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $10,965.68 7
PY2025 Principal investigator $118,898.68 26
PY2024 Recipient $940.00 1
PY2024 Principal investigator $94,307.55 10
PY2023 Recipient $4,140.00 2
PY2023 Principal investigator $20,212.00 17
PY2022 Recipient $1,509.92 3
PY2022 Principal investigator $36,457.90 41
PY2021 Recipient $12,480.00 6
PY2021 Principal investigator $35,842.40 23
PY2020 Principal investigator $20,540.96 7
PY2019 Recipient $75,243.57 2
PY2019 Principal investigator $3,135.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

33 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,537.36 12/31/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202535053
Recipient Takeda Pharmaceuticals U.S.A., Inc. $46.40 12/31/2025 Covered Recipient Physician A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo. No dispute reported 06/30/2026 1223262864
Recipient PFIZER INC. $1,820.00 12/23/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727541
Recipient PFIZER INC. $1,820.00 12/19/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727497
Principal investigator 1 ABBVIE INC. $800.00 12/11/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202530262
Principal investigator 1 ABBVIE INC. $7,361.52 12/04/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202528722
Principal investigator 1 Incyte Corporation $1,383.00 12/04/2025 Non-covered Recipient Entity
ACRC TRIALS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240498375
Principal investigator 1 ABBVIE INC. $1,800.00 12/02/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202526308
Principal investigator 1 Incyte Corporation $535.00 11/14/2025 Non-covered Recipient Entity
ACRC TRIALS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240498371
Principal investigator 1 ABBVIE INC. $429.43 11/06/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202523221
Principal investigator 1 ABBVIE INC. $15,624.56 11/05/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202521449
Recipient Takeda Pharmaceuticals U.S.A., Inc. $9.28 11/01/2025 Covered Recipient Physician A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo. No dispute reported 06/30/2026 1223262862
Recipient ABBVIE INC. $6,000.00 09/22/2025 Covered Recipient Physician A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Pediatric Subjects 6 to <12 Years Old with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202397932
Principal investigator 1 ABBVIE INC. $800.00 09/16/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202511000
Principal investigator 1 Incyte Corporation $2,416.00 09/12/2025 Non-covered Recipient Entity
ACRC TRIALS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240498366
Principal investigator 1 ABBVIE INC. $11,454.82 09/04/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202508658
Principal investigator 1 Incyte Corporation $8,000.00 08/14/2025 Non-covered Recipient Entity
ACRC TRIALS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240498351
Principal investigator 1 Incyte Corporation $1,500.00 08/14/2025 Non-covered Recipient Entity
ACRC TRIALS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240498355
Principal investigator 1 Incyte Corporation $2,000.00 08/14/2025 Non-covered Recipient Entity
ACRC TRIALS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240498363
Principal investigator 1 Incyte Corporation $535.00 08/07/2025 Non-covered Recipient Entity
ACRC TRIALS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240498359
Principal investigator 1 ABBVIE INC. $7,345.53 07/02/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202496681
Principal investigator 1 Incyte Corporation $1,383.00 06/19/2025 Non-covered Recipient Entity
ACRC TRIALS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240498344
Recipient PFIZER INC. $940.00 06/07/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228753972
Principal investigator 1 Incyte Corporation $12,708.00 06/05/2025 Non-covered Recipient Entity
ACRC TRIALS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240498348
Principal investigator 1 ABBVIE INC. $6,161.28 06/03/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202488645
Principal investigator 1 ABBVIE INC. $5,943.72 05/07/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202483029
Recipient PFIZER INC. $330.00 05/06/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228753051
Principal investigator 1 ABBVIE INC. $5,463.48 04/03/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202472049
Principal investigator 1 ABBVIE INC. $10,638.96 03/07/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202459157
Principal investigator 1 ABBVIE INC. $5,134.49 02/06/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202448455
Principal investigator 1 ABBVIE INC. $125.00 01/30/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202443163
Principal investigator 1 ABBVIE INC. $1,300.00 01/29/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202441836
Principal investigator 1 ABBVIE INC. $4,518.53 01/02/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202434921